An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.
Study findings were published...
HOUSTON – The University of Texas MD Anderson Children’s Cancer Hospital joins Peli Peli Restaurants, the National Association for Catering...
The University of Texas MD Anderson Cancer Center proudly presents End Cancer Night at BBVA Compass Stadium Saturday, April 27 at 7 p.m. as...